Kornimate/medical-research-clean huggingface dataset:
lsd treatment for persons with alcohol use disorder

Conditions: Alcohol Use Disorder (AUD)

Summary: alcohol use causes more overall harm than any other drug and is the seventh leading risk factor for both deaths and disability-adjusted life years. alcohol use disorders (aud) are among the most common and undertreated mental disorders in developed countries. pharmacological and psychotherapeutic treatments only show limited efficacy and around 60% of the patients relapse in the short-term after withdrawal. lysergic acid diethylamide (lsd) was investigated in numerous clinical trials during the 1950s and 1960s. specifically, the use of lsd in the treatment of aud was investigated extensively. a pooled analysis of six historical clinical trials demonstrated, that a single dose of lsd significantly reduced alcohol use at three and six months after lsd administration. however, these trials are limited by several factors, including the use of diagnostic standards that are no longer not up to date, single, high-dose treatment regimes, missing biological assessment for alcohol use, and no consequent assessment of blinding. therefore, the present study aims to evaluate the safety and efficacy of lsd for the treatment of aud and addresses the shortcomings of previous studies. the trial has a double-blind, active placebo-controlled, randomized, parallel design and will be conducted in specialized treatment centers for addictive disorders in switzerland. the study will include 126 patients after withdrawal treatment and will primarily assess the efficacy of lsd for the treatment of aud. patients will be treated using a 1:1 allocation. each arm will last 20 weeks and will comprise nine study visits without drug administration and two study days involving lsd or active placebo administration. in the first session, patients in the treatment group will receive a dose of 150 µg lsd, followed by another 150 µg or 250 µg lsd in the second session, which will take place approximately 4 weeks after the first session. the primary outcome is the mean of percent heavy drinking days after administration of two doses of lsd at 3 months follow-up. additionally, the study will assess neurobiological mechanisms of action and several other measures.


Eligibility criteria:
key inclusion criteria: * age ≥ 25 years * moderate to severe aud * completion of a qualified detoxification for aud within 30 days prior to screening * a minimum of 4 heavy drinking days within the last 30 days before detoxification * intention to stop or decrease drinking key exclusion criteria: * significant alcohol withdrawal symptoms at screening * participating or starting in any formal treatment for aud until completion of visit 9 * cognitive impairment * borderline personality disorder * current post-traumatic stress disorder * current suicidality or history of a serious suicide attempt * significant prodromal symptoms * history of a diagnosis of a psychotic or bipolar disorder in subjects or first-degree relatives * pregnancy or breast-feeding * lack of safe contraception are exclusion criterion for women only
a study of daclatasvir and sofosbuvir with ribavirin in subjects with cirrhosis and genotype 3 hepatitis c infection

Conditions: Hepatitis C

Summary: the purpose of this study is to determine whether 24 weeks of daclatasvir and sofosbuvir with ribavirin is safe and effective in the treatment of genotype 3 hepatitis c infected patients with liver cirrhosis.


Eligibility criteria:
for more information regarding bristol-myers squibb (bms) clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * genotype 3 hcv * hcv rna ≥10000 iu (international unit)/ml * compensated liver cirrhosis * bmi 18-40 kg/m2 * previously treated for hcv or never treated for hcv exclusion criteria: * infection with hcv other than genotype 3. mixed infection of any genotype * evidence of decompensated liver disease * previous exposure to ns5a inhibitors other protocol defined inclusion/exclusion criteria could apply
a 28 day study of ono-9054 ophthalmic solution in subjects with ocular hypertension (oht) or open-angle glaucoma (oag)

Conditions: Ocular Hypertension; Open Angle-glaucoma

Summary: the primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (iop) of ono-9054 30 µg/ml (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.


Eligibility criteria:
inclusion criteria: * male or female aged 18-85 (inclusive) with confirmed diagnosis of oht or oag * confirmed diagnosis of bilateral oht or mild to moderate chronic oag * able to undergo washout of all ocular drugs * an iop ≥ 24 mmhg at 8:00 am and ≥ 21 mmhg at 10:00 am in at least 1 eye; but \< 36 mmhg in both eyes at both day -5 and day 1 * central corneal thickness 500-620 µm at screening and day -5 in both eyes * best corrected visual acuity (bcva) of +0.7 log mar or better exclusion criteria: * any history of severe ocular trauma in either eye at any time * history of angle closure or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of screening visit in the study eye(s) * cataracts that prevent observation or photography of the fundus in either eye

Keywords: ono-9054 ocular hypertension (oht) open angle-glaucoma (oag) glaucoma eye diseases mild to moderate
evaluation of the bhx implant in children with a bahs

Conditions: Hearing Loss, Conductive

Summary: the purpose of this study is to in a proactive manner collect high quality data from pediatric patients who have undergone a bone anchored hearing surgery, using the ponto bhx implant, in clinical practice. this to further increase the knowledge of bone anchored hearing systems in the pediatric population.


Eligibility criteria:
inclusion criteria: 1. patients who have decided to undergo a bone anchored hearing surgery and receive a ponto system. 2. signed informed consent. 3. patients between 5 - 16 years of age. 4. patients eligible for one stage surgery. 5. patients who have been using ponto sound processor on a soft band for at least 2 weeks. exclusion criteria: 1. patients who cannot attend follow up visits. 2. patients with single side deafness (ssd). 3. in surgeon's opinion, any other disorder and condition that may deem the patient unfit to participate in the study. 4. patients who receive other implant than the ponto bhx. -
novel therapy target in metastatic prostate cancer

Conditions: Prostate Neoplasms

Summary: the aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mpca), especially metastatic castration-resistant prostate cancer (mcrpc). at the same time, mcrpc models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mpca.

although substantial progress in treatments for prostate cancer have been made in the past decades, distant metastasis and drug resistance remained a major cause of prostate cancer-related deaths. the five-year survival rate for men with mpca was only 30% and all patients with mpca would inevitably progress to the castration-resistant stage with limited therapeutic chance. in china, the current situation is more worrying, with rapidly increasing pca incidence and higher proportion of mpca diagnosed compared with the western nations (\~30% vs \~5%). multiomics sequencing provides a promising strategy to discover the underlying molecular basis driving metastasis and resistance and identify the new treatment strategies for patients with mcrpc. the candidate drug target revealed by the multiomics sequencing could be further examined in the organoid and animal models, facilitating the clinical application from basic discovery. this study can establish a mcrpc research system to find the molecular mechanism and potential intervention targets of mcrpc, thereby paving the way for the discovery of new treatments for mcrpc patients.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed prostate cancer 2. metastatic disease confirmed by image examination 3. patients who can undergo surgery or biopsy for prostate cancer 4. able to provide informed consent exclusion criteria: 1. patients diagnosed with other types of cancer besides prostate cancer 2. not accessible to surgery sample 3. patients fail to provide informed consent 4. other situation that researchers think are unsuitable for this study

Keywords: prostate cancer multi-omics organoid
multipurpose disinfecting solution compatibility with a silicone hydrogel contact lens

Conditions: Myopia; Hyperopia

Summary: the purpose of this study is to verify the compatibility of a silicone hydrogel lens when used with four multipurpose disinfecting solutions (opti-free® replenish®, renu multiplus®, solo-care aqua™ and menicaretm soft).

the purpose of this study is to verify the compatibility of a silicone hydrogel lens when used with four multipurpose disinfecting solutions (opti-free® replenish®, renu multiplus®, solo-care aqua™ and menicaretm soft) by observing changes within the cornea.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: 1. is at least 17 years old and has full legal capacity to volunteer 2. has read and signed an information consent letter, after having the opportunity to ask questions and receive acceptable answers 3. is willing and able to follow instructions and maintain the study appointment schedule 4. is correctable to a visual acuity of 6/7.5 (20/25) or better (both eyes) with their habitual vision correction 5. has normal binocular vision (no strabismus, no amblyopia, and anisometropia less than or equal to 1.00 d) 6. has clear corneas and no active ocular disease 7. has had an ocular examination in the last two years. 8. has a functional pair of spectacles 9. is a current soft lens wearer replacing their lenses at least monthly 10. has a distance contact lens prescription between +6.00d to -10.00 ds and can be successfully fitted with the study lens 11. has astigmatism less than or equal to -1.00dc 12. agrees to wear the study lenses on a daily wear basis exclusion criteria: a person will be excluded from the study if he/she: 1. has any signs or symptoms of dry eye 2. has any clinically significant blepharitis 3. has undergone corneal refractive surgery 4. is aphakic 5. has any systemic disease affecting ocular health 6. is using any systemic or topical medications that may affect ocular health 7. is pregnant or lactating 8. is participating in any other type of clinical or research study 9. currently wears daily disposable lenses 10. currently wears lenses on a continuous or extended wear basis 11. is unable to successfully wear contact lenses without routinely using rewetting drops
epidural block impairs hpv during one-lung ventilation: an eit- based prospective observation study

Conditions: Epidural Block; Electrical Impedance Tomography

Summary: define the effect of epidural block on hpv by eit.

epidural block may affect the physiological mechanism of hypoxic pulmonary vasoconstriction, which is still poorly understood. electrical impedance tomography might be helpful in establishing the hypoxemia etiology at bedside via combining regional ventilation and perfusion information.

Eligibility criteria:
inclusion criteria: * age 18 - 80 years existing central venous and arterial access chest circumference 70 - 150 cm exclusion criteria: * contraindication to central venous injection of 5 % sodium chloride (nacl) contraindications of pulmovista 500: patients with pacemakers, defibrillators or other electrically active implants patients with damaged skin or impaired skin contact of the electrodes due to wound dressings patients where the attachment of the patient belt could pose a risk to the patient, e.g. patients with spinal lesions or fractures patients with uncontrolled body movements extremely obese patients (bmi\>50) patients during pregnancy patients with massive lung edema use during electricity-based therapies, such as electrosurgery or electrocautery use in the presence of strong magnetic fields use in conjunction with other bioimpedance measurement devices
a tiered management system of osteoporosis in china

Conditions: Osteoporosis; Osteopenia

Summary: there is a management gap in china. this study aims to establish a tiered management system of osteoporosis for chinese patients. including: 1. developing a national hierarchical health management network platform for middle-aged and elderly osteoporosis patients. with this platform, the data of medical records, laboratory results would be shared between medical institutions. and primary hospitals can refer the patients to the nearest medical centre for advanced auxiliary examinations and diagnosis. 2. establishing a muti-level hospital collaboration, doctor-patient interaction management model of osteoporosis. 3. to explore and establish a early warning and screening pathways for osteoporosis.


Eligibility criteria:
inclusion criteria: * postmenopausal women or men aged 50 years or older conform to the diagnosis of osteoporosis or osteopenia as followings: 1. bone mineral density measured by dual-energy x-ray absorptiometry show a t-score ≤ -1.0 at neck of femur or total hip or lumber 1-4 or 2. have at least once major osteoporotic fracture exclusion criteria: * screened people who do not meet the inclusion criteria
stem cell transplantation to treat high risk multiple myeloma with reduced toxicity myeloablative conditioning regimen

Conditions: Multiple Myeloma; Plasma Cell Leukemia

Summary: standard therapy for multiple myeloma (mm) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are transplanted back into their body. patients with multiple myeloma and high risk genes, always relapse after an autologous transplant and often die within two years from the time of their transplant. a different type of transplant allogeneic) using donor cells, may work better for high-risk multiple myeloma, because the donor cells may help kill the lymphoid cancer cells. this study will investigate if a matched donor stem cell transplant using a newer, reduced toxicity, chemotherapy (flu-bu4) is a feasible option for patients with high risk, multiple myeloma.


Eligibility criteria:
inclusion criteria: * biologic high risk multiple myeloma: * stage ii/iii multiple myeloma, any of: t(4; 14), t(14; 16),(14:20) by fish; 17p- by conventional cytogenetics or fish; ∆13 by conventional cytogenetics; hypodiploidy by conventional cytogenetics. * relapsed or persistent multiple myeloma after asct. * persistent multiple myeloma, regardless of previous therapies. * plasma cell leukemia, regardless of previous therapies. * age up to 70 years old (less than 71 years old at the date of transplant admission). * disease status: in cr, ncr, vgpr, pr or stable disease within 1 month of admission * patients with non-secretory and oligosecretory disease are eligible if they meet certain criteria within 2 weeks prior to the transplant. * specific renal, liver, cardiac, and pulmonary function requirements(all must be met within 30 days of transplant admission) exclusion criteria: * persistent invasive infections, not controlled by antimicrobials. * hiv-1/hiv-2 or htlv-1/htlv-2 seropositivity. * uncontrolled medical or psychiatric disorder. * no response or progressive disease at the time of transplantation. * pregnancy

Keywords: stage ii/iii multiple myeloma(within 10 months from diagnosis) high risk relapse persistent
use of acthar in patients with fsgs that will be undergoing renal transplantation

Conditions: FSGS

Summary: this study will evaluate the use of acthar in patients to undergo renal transplantation and will measure the rate of fsgs recurrence.

this is a prospective study enrolling renal transplant recipients with the primary native kidney disease of fsgs. primary endpoint is rate of recurrence of fsgs as seen in renal transplant biopsies and in rate of proteinuria. secondary endpoint is renal function after transplantation the target subject number is 20 patients and the target population is primary fsgs patients. by the current data, fsgs should recur in 23% of patients. therefore, it would be expected that at least 4 patients will develop recurrent fsgs after renal transplantation. screening will be performed by the principal investigator during the kidney transplant evaluation clinics and during the wait list kidney transplant evaluation clinic. all patients with fsgs will have maintenance immunosuppression with belatacept (if ebv positive), prograf, cellcept and prednisone. if after one year the patient has been stable and there has not been rejection, will stop the prograf and continue solely with belatacept, cellcept and prednisone. dosage and administration of acthar the dose of acthar to be given to every enrolled patient will be 80 units twice a week for 6 months.

Eligibility criteria:
inclusion criteria: * fsgs * to receive either a live donor or deceased donor kidney transplant exclusion criteria: * not having fsgs

Keywords: kidney transplant
saliva and dental calculus in handicapped people

Conditions: Disabled Persons

Summary: this is an evaluation of potential differences in saliva composition and dental calculus composition between orally fed and tube fed individuals in an institutional environment.


Eligibility criteria:
inclusion criteria: * handicapped (mentally and/or physically) persons in an institute * older than 5 years of age * both sexes * full medical records available exclusion criteria: * healthy individuals * disabled individuals not staying in an institution

Keywords: handicapped individuals
acetazolamide to prevent impending altitude-illness in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease; Altitude Sickness; Altitude Hypoxia

Summary: the purpose of this randomized, placebo-controlled double-blind trial is to evaluate efficacy of acetazolamide in preventing overt altitude-related adverse health effects (arahe) in lowlanders with chronic obstructive pulmonary disease (copd) developing early signs of altitude-illness during altitude travel.

this randomized placebo-controlled, double-blind, parallel-design trial will evaluate effectiveness of acetazolamide in reducing the incidence of predefined altitude-related adverse health effects in lowlanders with chronic obstructive pulmonary disease (copd) travelling to high altitude and developping early symptoms and/or signs of impending altitude-illness. qualifying participants will be randomized 1:1 to acetazolamide or placebo treatment during their further stay of 2 days at 3'100 m. an interim-analysis will be performed after the first year of the study or when 38 participants are randomized, whichever comes first. symmetric stopping boundaries at p\<0.001 will be applied (peto approach).

Eligibility criteria:
inclusion criteria * men and women, age 35-75 y, living at low altitude (\<800 m). * copd diagnosed according to the global initiative for obstructive lung disease (gold) guidelines, forced expiratory volume in one second 40-80% predicted, pulse oximetry ≥92%, paco2 \<6 kilopascal, breathing ambient air at 760 m. * one of the following early signs and/or symptoms of impending altitude-illness identified by self-monitoring during ascent to or stay at 3100 m: * pulse oximetry spo2≤84% * headache or nausea/vomiting or fatigue/weakness or dizziness/light-headedness of at least moderate intensity exclusion criteria * copd exacerbation, very severe copd with hypoxemia or hypercapnia at 760 m (see above). * other lung disease, relevant comorbidities (such as uncontrolled cardiovascular disease, i.e., unstable arterial hypertension, coronary artery disease; previous stroke; obesity (body mass index \>35 kg/m2); internal, neurologic, rheumatologic or psychiatric disease; current heavy smoking (\>20 cigarettes per day). * renal failure and/or allergy to sulfonamides. * patients who do not have early signs and/or signs of impending altitude-illness by self-monitoring (as defined above) at 3'100m will not be included.

Keywords: acetazolamide mountain sickness hypoxemia prevention
opioid-induced hyperalgesia after remifentanil infusion

Conditions: Hyperalgesia

Summary: remifentanil is a rapid-acting opioid which has been widely used in pain treatment during surgery for the last 15 years 1. remifentanil is rapidly eliminated (minutes) from the body after end of infusion, and this makes it easily manageable compared to other opioids. however, there are both experimental and clinical studies indicating that remifentanil, after end of infusion, triggers increased pain sensation and increased opioid consumption post-operatively. increased post-operative opioid consumption should be avoided due to the adverse effects of these drugs (nausea/vomiting, pruritus, dizziness, fatigue and reduced respiratory rate). thus, it's important to investigate relevant strategies to avoid the increased pain sensation (opioid-induced hyperalgesia = hypersensitivity to pain stimuli) after end of infusion of remifentanil after surgery. several experimental and clinical trials have been conducted in this field. ketamine has been shown to block this effect, but its adverse effect profile (i.a. hallucinations) makes it not suitable in normal clinical use. in a study of healthy volunteers, it has been demonstrated that parecoxib (a cox-2 selective nsaid) can prevent remifentanil-induced hyperalgesia. our group has previously shown that a relatively cox-1 selective nsaid (ketorolac) can prevent hyperalgesia in an experimental pain model. this is of interest since nsaids are frequently administered as premedication before surgery. there are several disadvantages associated with the use of cox-2 inhibitors, e.g. the risk of myocardial infarction after long-term use (\> 1 year), and potentially reduced bone healing after orthopedic surgery. however, this has not been shown with short-term use (days/week). the disadvantages associated with the use of e.g. ketorolac (a cox-1 inhibitor) are i.a. increased bleeding tendency, which is unfavourable for the surgeon, and increased risk of gastric ulcer. therefore, it is of interest to investigate other ways of preventing opioid-induced hyperalgesia. in a recent animal study it has been shown that gradual dose reduction of remifentanil (vs. abrupt withdrawal of a relatively high remifentanil dose) can prevent the development of hyperalgesia after end of infusion. in this study we will i.a. investigate whether this is also the case in humans. in this new model, the study participants will get remifentanil infusion with two different dose reduction regimes: gradual reduction or abrupt withdrawal.


Eligibility criteria:
inclusion criteria: * male * age 18-60 * body mass index 17-30 * healthy volunteers exclusion criteria: * use of medication; alternative medicine * substance abuse * allergies towards medication used in the study * participation in other clinical studies the previous 6 months

Keywords: opioid induced hyperalgesia pain postoperative pain hyperalgesia